To study associations of polymorphic variants of dopamine receptor genes with efficacy and safety parameters of antipsychotics in adolescents with an acute psychotic episode.
Material and methods
The prospective observational study included 101 adolescents diagnosed with acute polymorphic psychotic disorder at the time of admission. Patients were followed up for 14 days. All patients received an antipsychotic as their main therapy. The following scales were used to assess the efficacy and safety of therapy on day 14: CGAS, PANSS, CGI-S, CGI-I, UKU SERS, SAS, BARS. The determination of polymorphic variants of DRD2 (rs1800497, C>T), DRD3 (rs6280, C>T), DRD3 (rs324026, C>T), and DRD4 (rs1800955, C>T) genes was performed by real-time polymerase chain reaction (PCR).
Carriers of the TT homozygote of the DRD3 rs6280 polymorphic variant had no significant change in the PANSS “Negative Symptoms” subscale score during treatment. Carriage of DRD2 rs1800497 CT+TT was associated with a more pronounced reduction in the PANSS subscale score “productive symptomatology” on day 14 compared with carriers of the CC genotype (-7.00 [-9; -5.75] vs. -6.00 [-8; -2]; p=0.008). Carriers of the TT DRD3 rs6280 homozygote had less intense dreams and subjective severity of adverse drug effects compared to carriers of the “wild” allele C. Carriers of the CT+TT DRD2 rs1800497 genotype had a higher mean SAS score relative to the CC genotype (2.00 [1; 3.25] vs. 1.00 [0; 2]; p=0.016). Haplotype analysis of the DRD3 polymorphic variants rs324026 and rs6280 showed no statistically significant associations with the efficacy and safety of treatment.
The DRD2 rs1800497 and DRD3 rs6280 polymorphic variants were significantly associated with the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode.
Pharmacogenetics, antipsychotics, adoles- cents, DRD2, DRD3.